References

1. Creutzig U, Ritter J, Zimmermann M, et al (2001) Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 19:2705-2713

2. Stiller CA, Benjamin S, Cartwright RA, et al (1999) Patterns of care and survival for adolescents and young adults with acute leukaemia - a population-based study. Br J Cancer 79:658-665

3. Bleyer WA, O'Leary M, Barr R, Ries LAG (eds) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications

4. Ries LAG, Eisner MP, Kosary CL, et al (2003) National Cancer Institute SEER Cancer Statistics Review, 19752000. http://seercancergov/csr/1975_2000. National Cancer Institute, Bethesda, MD

5. ACCIS (2003) Automated Childhood Cancer Information System. http://www-depiarcfr/accis/datahtm

6. German Childhood Cancer Registry (GCCR) (2003) Annual Report 2002. http://infoimsduni-mainzde/K_ Krebsregister/english/ . 14-10-2003

7. Kaatsch P, Spix C, Michaelis J (2002) Jahresbericht 2000 Deutsches Kinderkrebsregister (1st edn) Deutsches Kinderkrebsregister, Mainz

8. Hjalgrim LL, Rostgaard K, Schmiegelow K, et al (2003) Age- and sex-specific incidence of childhood leukemia by immunophenotype in the Nordic countries. J Natl Cancer Inst 95:1539-1544

9. Birch JM, Alston RD, Kelsey AM, et al (2002) Classification and incidence of cancers in adolescents and young adults in England 1979-1997. Br J Cancer 87:1267-1274

10. Reedijk AMJ, Janssen-Heijnen MLG, Louwman MWJ, et al (2005) Increasing incidence and improved survival of cancer in children and young adults in Southern Netherlands, 1973-1999. Eur J Cancer 41:760-769

11. Messerer D, Dugas M, Müller T, Hasford J (2003) How many patients with AML were treated in clinical trials in Germany? Rundbrief Kompetenznetz Leukämien 5:6-7

12. Crisphino JD (2005) GATA 1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 16:137-147

13. Hitzler JK, Zipursky A (2005) Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 5:1120.

14. Ge Y, Stout ML, Tatman DA, et al. (2005) GATA 1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer inst 97:226-231

15. Löning L, Zimmermann M, Reiter A, et al (2000) Secondary neoplasms subsequent to Berlin-FrankfurtMunster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 95:2770-2775

16. Pui CH, Hancock ML, Raimondi SC, et al (1990) Myeloid neoplasia in children treated for solid tumours. Lancet 336:417-421

17. Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 38:1-10

18. Vickers M, Jackson G, Taylor P (2000) The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 14:722-726

19. Douer D, Preston-Martin S, Chang E, et al (1996) High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 87:308313

20. Hann IM, Stevens RF, Goldstone AH, et al (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Councils 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89:2311-2318

21. Lie SO, Abrahamsson J, Clausen N, et al(2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 122:217-225

22. Stevens RF, Hann IM, Wheatley K, Gray RG, on behalf of the MRC Childhood Leukaemia Working Party (1998) Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 101:130-140

23. Davies SM, Robison LL, Buckley JD, et al (2001) Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19:1279-1287

24. Büchner T, Heinecke A (1996) The role of prognostic factors in acute myeloid leukemia. Leukemia 10:S28-S29

25. Wells RJ, Woods WG, Buckley JD, et al (1994) Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group Study. J Clin Oncol 12:2367-2377

26. Wells RJ, Arthur DC, Srivastava A, et al (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-607

27. Horibe K, Tsukimoto I, Ohno R (2001) Clinicopatho-logic characteristics of leukemia in Japanese children and young adults. Leukemia 15:1256-1261

28. Büchner T, Hiddemann W, Berdel WE, et al (2003) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21:4496-4504

29. Jeha S, Smith FO, Estey E, et al (2002) Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk Res 26:399-402

30. Creutzig U, Zimmermann M, Reinhardt D, Büchner T (2004) AML in adolescents compared to AML in children and young adults. Proceedings of the Fourth Biennial Hannover Symposium on Childhood Leukemia, May 3-5, 2004, Hannover, Germany

31 Woods WG, Alonzo TA, Lange BJ, et al (2001) Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): a comparison of outcomes between patients treated on childhood or adult protocols (abstract). Blood 98:462a-463a

32. Steinbach D, Furchtbar S, Sell W, et al (2003) Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia 17:470-471

33. Bacher U, Kern W, Schnittger S, et al (2005). Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 90:1502-1510

34. Vormoor J, Ritter J, Creutzig U, et al (1992) Acute myelogenous leukaemia in children under 2 years -experiences of the West German AML Studies BFM-78, -83 and -87. Br J Cancer 66:63-67

35. Ruiz-Arguelles GJ (1997) Promyelocytic leukemia in Mexican Mestizos. Blood 89:348-349

36. Douer D, Estey E, Santillana S, et al (2001) Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 97:73-80

37. Guidez F, Ivins S, Zhu J, et al (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634-2642

38. Penson RT, Rauch PK, McAfee SL, et al (2002) Between parent and child: negotiating cancer treatment in adolescents. Oncologist 7:154-162

39. Lie SO, Jonmundsson G, Mellander L, et al (1996) A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 94:82-88

40. Benjamin S, Kroll ME, Cartwright RA, et al (2000) Haematologists' approaches to the management of adolescents and young adults with acute leukaemia. Br J Haematol 111:1045-1050

41. Bleyer A (2002) Older adolescents with cancer in North America deficits in outcome and research. Pediatr Clin North Am 49:1027-1042

42. Bleyer WA, Tejeda H, Murphy SB, et al (1997) National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health 21:366-373

43. Schiffer CA (2003) Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol 21:760-761

44. Robison LL, Bhatia S (2003) Late effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 122:345-359

45. Buzdar AU, Marcus C, Smith TL, Blumenschein GR (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55:2761-2765

46. Brennan BM, Shalet SM (2002) Endocrine late effects 47. Leiper AD (2002) Non-endocrine late complications of after bone marrow transplant. Br J Haematol 118:58- bone marrow transplantation in childhood: part II. Br J

66 Haematol 118:23-43

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment